MediWound Ltd. (MDWD)
MediWound Ltd. (MDWD) Stock Price, Analysis & Data
| Bid | 10.22 |
| Market Cap | 172.09M |
| Revenue (ttm) | 11.86M |
| Net Income (ttm) | -20.18M |
| Beta | 0.16 |
| EPS (ttm) | -2.16 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.85 |
| P/B (ttm) | 4.16 |
| P/S (ttm) | 14.51 |
| Earnings Date | Nov 19, 2026 |
| Ask | 18.25 |
| Volume | 73,840 |
| Avg. Volume (20D) | 87,100 |
| Open | 13.52 |
| Previous Close | 13.56 |
| Day's Range | 13.29 - 13.90 |
| 52-Week Range | 13.29 - 20.30 |
| Analyst | Strong Buy |
| Price Target | 30 (124.05%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops Esc...
Financial Performance
In 2025, MediWound's revenue was 16.96M, a decrease of -16.14% compared to the previous year's 20.22M. Earnings were -23.88M, a decrease of -20.99%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for MDWD stock is "Strong Buy". The 12-month stock price forecast is 30, which is upside of 124.05% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
